Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study

<p>Coronavirus disease 2019 (COVID-19) increases the risk of coagulopathy. Although the presence of antiphospholipid antibodies (aPLs) has been proposed as a possible mechanism of COVID-19-induced coagulopathy, its clinical significance remains uncertain. Therefore, this study aimed to evaluat...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Mostafa Najim (14150400) (author)
مؤلفون آخرون: Alaa Rahhal (14150403) (author), Fadi Khir (14150406) (author), Amer Hussien Aljundi (14150409) (author), Safae Abu Yousef (14150412) (author), Feryal Ibrahim (14150415) (author), Aliaa Amer (14150418) (author), Ahmed S. Mohamed (11659456) (author), Samira Saleh (11722049) (author), Dekra Alfaridi (14150421) (author), Ahmed Mahfouz (737928) (author), Sumaya Alyafei (14147868) (author), Faraj Howady (9617064) (author), Mohamad Khatib (5240345) (author), Samar A. Alemadi (14150424) (author)
منشور في: 2022
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513568054968320
author Mostafa Najim (14150400)
author2 Alaa Rahhal (14150403)
Fadi Khir (14150406)
Amer Hussien Aljundi (14150409)
Safae Abu Yousef (14150412)
Feryal Ibrahim (14150415)
Aliaa Amer (14150418)
Ahmed S. Mohamed (11659456)
Samira Saleh (11722049)
Dekra Alfaridi (14150421)
Ahmed Mahfouz (737928)
Sumaya Alyafei (14147868)
Faraj Howady (9617064)
Mohamad Khatib (5240345)
Samar A. Alemadi (14150424)
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author_facet Mostafa Najim (14150400)
Alaa Rahhal (14150403)
Fadi Khir (14150406)
Amer Hussien Aljundi (14150409)
Safae Abu Yousef (14150412)
Feryal Ibrahim (14150415)
Aliaa Amer (14150418)
Ahmed S. Mohamed (11659456)
Samira Saleh (11722049)
Dekra Alfaridi (14150421)
Ahmed Mahfouz (737928)
Sumaya Alyafei (14147868)
Faraj Howady (9617064)
Mohamad Khatib (5240345)
Samar A. Alemadi (14150424)
author_role author
dc.creator.none.fl_str_mv Mostafa Najim (14150400)
Alaa Rahhal (14150403)
Fadi Khir (14150406)
Amer Hussien Aljundi (14150409)
Safae Abu Yousef (14150412)
Feryal Ibrahim (14150415)
Aliaa Amer (14150418)
Ahmed S. Mohamed (11659456)
Samira Saleh (11722049)
Dekra Alfaridi (14150421)
Ahmed Mahfouz (737928)
Sumaya Alyafei (14147868)
Faraj Howady (9617064)
Mohamad Khatib (5240345)
Samar A. Alemadi (14150424)
dc.date.none.fl_str_mv 2022-11-22T21:12:06Z
dc.identifier.none.fl_str_mv 10.1007/s00296-021-04875-7
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Prevalence_and_clinical_significance_of_antiphospholipid_antibodies_in_patients_with_coronavirus_disease_2019_admitted_to_intensive_care_units_a_prospective_observational_study/21597003
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Immunology
Immunology
Immunology and Allergy
Rheumatology
dc.title.none.fl_str_mv Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <p>Coronavirus disease 2019 (COVID-19) increases the risk of coagulopathy. Although the presence of antiphospholipid antibodies (aPLs) has been proposed as a possible mechanism of COVID-19-induced coagulopathy, its clinical significance remains uncertain. Therefore, this study aimed to evaluate the prevalence and clinical significance of aPLs among critically ill patients with COVID-19. This prospective observational study included 60 patients with COVID-19 admitted to intensive care units (ICU). The study outcomes included prevalence of aPLs, and a primary composite outcome of all-cause mortality and arterial or venous thrombosis between antiphospholipid-positive and antiphospholipid-negative patients during their ICU stay. Multiple logistic regression was used to assess the influence of aPLs on the primary composite outcome of mortality and thrombosis. A total of 60 critically ill patients were enrolled. Among them, 57 (95%) were men, with a mean age of 52.8 ± 12.2 years, and the majority were from Asia (68%). Twenty-two patients (37%) were found be antiphospholipid-positive; 21 of them were positive for lupus anticoagulant, whereas one patient was positive for anti-β2-glycoprotein IgG/IgM. The composite outcome of mortality and thrombosis during their ICU stay did not differ between antiphospholipid-positive and antiphospholipid-negative patients (4 [18%] vs. 6 [16%], adjusted odds ratio 0.98, 95% confidence interval 0.1–6.7; p value = 0.986). The presence of aPLs does not seem to affect the outcomes of critically ill patients with COVID-19 in terms of all-cause mortality and thrombosis. Therefore, clinicians may not screen critically ill patients with COVID-19 for aPLs unless deemed clinically appropriate.</p><h2>Other Information</h2> <p> Published in: Rheumatology International<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s00296-021-04875-7" target="_blank">http://dx.doi.org/10.1007/s00296-021-04875-7</a></p>
eu_rights_str_mv openAccess
id Manara2_447f330587adb2e9bc3e87c5706f461e
identifier_str_mv 10.1007/s00296-021-04875-7
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/21597003
publishDate 2022
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational studyMostafa Najim (14150400)Alaa Rahhal (14150403)Fadi Khir (14150406)Amer Hussien Aljundi (14150409)Safae Abu Yousef (14150412)Feryal Ibrahim (14150415)Aliaa Amer (14150418)Ahmed S. Mohamed (11659456)Samira Saleh (11722049)Dekra Alfaridi (14150421)Ahmed Mahfouz (737928)Sumaya Alyafei (14147868)Faraj Howady (9617064)Mohamad Khatib (5240345)Samar A. Alemadi (14150424)ImmunologyImmunologyImmunology and AllergyRheumatology<p>Coronavirus disease 2019 (COVID-19) increases the risk of coagulopathy. Although the presence of antiphospholipid antibodies (aPLs) has been proposed as a possible mechanism of COVID-19-induced coagulopathy, its clinical significance remains uncertain. Therefore, this study aimed to evaluate the prevalence and clinical significance of aPLs among critically ill patients with COVID-19. This prospective observational study included 60 patients with COVID-19 admitted to intensive care units (ICU). The study outcomes included prevalence of aPLs, and a primary composite outcome of all-cause mortality and arterial or venous thrombosis between antiphospholipid-positive and antiphospholipid-negative patients during their ICU stay. Multiple logistic regression was used to assess the influence of aPLs on the primary composite outcome of mortality and thrombosis. A total of 60 critically ill patients were enrolled. Among them, 57 (95%) were men, with a mean age of 52.8 ± 12.2 years, and the majority were from Asia (68%). Twenty-two patients (37%) were found be antiphospholipid-positive; 21 of them were positive for lupus anticoagulant, whereas one patient was positive for anti-β2-glycoprotein IgG/IgM. The composite outcome of mortality and thrombosis during their ICU stay did not differ between antiphospholipid-positive and antiphospholipid-negative patients (4 [18%] vs. 6 [16%], adjusted odds ratio 0.98, 95% confidence interval 0.1–6.7; p value = 0.986). The presence of aPLs does not seem to affect the outcomes of critically ill patients with COVID-19 in terms of all-cause mortality and thrombosis. Therefore, clinicians may not screen critically ill patients with COVID-19 for aPLs unless deemed clinically appropriate.</p><h2>Other Information</h2> <p> Published in: Rheumatology International<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s00296-021-04875-7" target="_blank">http://dx.doi.org/10.1007/s00296-021-04875-7</a></p>2022-11-22T21:12:06ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s00296-021-04875-7https://figshare.com/articles/journal_contribution/Prevalence_and_clinical_significance_of_antiphospholipid_antibodies_in_patients_with_coronavirus_disease_2019_admitted_to_intensive_care_units_a_prospective_observational_study/21597003CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215970032022-11-22T21:12:06Z
spellingShingle Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study
Mostafa Najim (14150400)
Immunology
Immunology
Immunology and Allergy
Rheumatology
status_str publishedVersion
title Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study
title_full Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study
title_fullStr Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study
title_full_unstemmed Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study
title_short Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study
title_sort Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study
topic Immunology
Immunology
Immunology and Allergy
Rheumatology